Free Trial

GBS (GBS) Competitors

GBS logo
$1.90 -0.22 (-10.38%)
As of 07/24/2025

GBS vs. INFU, NSPR, CTCX, TMDIF, HSAQ, PETV, RVP, BTCY, INVO, and NAYA

Should you be buying GBS stock or one of its competitors? The main competitors of GBS include InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), Health Sciences Acquisitions Co. 2 (HSAQ), PetVivo (PETV), Retractable Technologies (RVP), Biotricity (BTCY), INVO Bioscience (INVO), and NAYA Biosciences (NAYA). These companies are all part of the "surgical & medical instruments" industry.

GBS vs. Its Competitors

GBS (NYSE:GBS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

2.8% of GBS shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 0.3% of GBS shares are owned by company insiders. Comparatively, 10.2% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InfuSystem has higher revenue and earnings than GBS. GBS is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GBSN/AN/A-$8.31M-$0.56-3.39
InfuSystem$137.58M0.92$870K$0.1442.93

In the previous week, InfuSystem had 8 more articles in the media than GBS. MarketBeat recorded 9 mentions for InfuSystem and 1 mentions for GBS. InfuSystem's average media sentiment score of 0.80 beat GBS's score of 0.25 indicating that InfuSystem is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GBS
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
InfuSystem
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GBS has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

InfuSystem has a consensus target price of $12.50, suggesting a potential upside of 107.99%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than GBS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GBS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
InfuSystem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
3 Strong Buy rating(s)
4.00

InfuSystem has a net margin of 1.12% compared to GBS's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GBS's return on equity.

Company Net Margins Return on Equity Return on Assets
GBSN/A -85.64% -54.42%
InfuSystem 1.12%2.78%1.41%

Summary

InfuSystem beats GBS on 15 of the 15 factors compared between the two stocks.

Get GBS News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBS vs. The Competition

MetricGBSSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$28.29M$66.04M$5.74B$21.13B
Dividend YieldN/AN/A4.60%3.58%
P/E Ratio-3.396.1628.1127.87
Price / SalesN/A139.16461.3759.63
Price / CashN/A18.4136.5523.02
Price / Book4.327.298.654.69
Net Income-$8.31M-$25.32M$3.25B$995.51M
7 Day Performance-11.21%0.54%4.20%1.64%
1 Month Performance6.74%3.04%10.82%5.92%
1 Year Performance28.38%53.10%34.70%11.50%

GBS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBS
GBS
N/A$1.90
-10.4%
N/A+46.2%$28.29MN/A-3.397
INFU
InfuSystem
3.3133 of 5 stars
$5.75
+4.4%
$12.50
+117.4%
N/A$115.80M$137.58M95.85410News Coverage
Analyst Forecast
Analyst Revision
NSPR
InspireMD
2.5395 of 5 stars
$2.51
-0.4%
$4.50
+79.3%
-14.4%$76.89M$7.03M-3.3550
CTCX
Carmell
N/A$3.63
-16.0%
N/A+316.0%$75.89M$32.84K0.0014
TMDIF
Titan Medical
N/A$0.38
+2.8%
N/A+979.5%$43.37M$17.63M-0.3050Gap Down
HSAQ
Health Sciences Acquisitions Co. 2
N/A$3.16
+2.3%
N/A-60.0%$35.43MN/A0.004
PETV
PetVivo
N/A$0.84
+0.6%
N/A+29.1%$20.41M$1.05M-1.8620
RVP
Retractable Technologies
1.9705 of 5 stars
$0.67
+0.8%
N/A-35.3%$20.06M$33.75M-1.24240
BTCY
Biotricity
N/A$0.51
+6.3%
N/A-34.7%$12.71M$12.06M-0.4740Analyst Revision
Gap Up
INVO
INVO Bioscience
N/A$2.55
+0.9%
N/AN/A$9.71M$5.77M0.0025Gap Up
NAYA
NAYA Biosciences
N/A$2.55
+0.9%
$24.00
+841.2%
N/A$1.22M$6.23M0.0010Gap Up
High Trading Volume

Related Companies and Tools


This page (NYSE:GBS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners